Trade Name: Brinavess
Vernakalant is a Class III antiarrhythmic agent administered intravenously for the acute cardioversion of recent-onset atrial fibrillation lasting less than 7 days. It predominantly blocks potassium channels, classifying it as a Class III antiarrhythmic; however, it exhibits an electrophysiologically selective effect on the atrial myocardium.
In 2010, its clinical administration was approved by the European Medicines Agency (EMA) for the indication of converting atrial fibrillation lasting less than 7 days, or post-operative atrial fibrillation lasting less than 3 days. The medication is strictly contraindicated if systolic blood pressure is < 100 mm Hg, or in cases presenting with severe aortic valve stenosis, heart failure, acute coronary syndrome within the preceding month, QT interval prolongation, and prior use of Class I or Class III antiarrhythmic agents. Adverse effects: Vernakalant is cleared from the organism within a few hours. During its presence, it may induce dysgeusia (taste disturbances), sneezing, and nausea, while cardiovascular adverse effects include hypotension, bradycardia, and ventricular arrhythmias.
It is noted that the drug has not yet received approval from the United States Food and Drug Administration (FDA). This is due to the fact that further clinical trial data were requested; in the conducted ACT V clinical study, a fatal outcome occurred following vernakalant administration secondary to cardiogenic shock. The evidence gathered to evaluate this incident was insufficient to definitively exclude the causal involvement of vernakalant. The study was prematurely terminated, and ultimately, the non-approval by the FDA discouraged further clinical research, which notably would have included the highly promising oral formulation of vernakalant.